STELIOS THERAPEUTICS
Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. The company is founded based on research conducted at the University of California San Diego (UCSD) by a distinguished team of researchers and scientists with extensive experience and expertise in gene therapy drug development.
STELIOS THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2017-01-01
Address:
Cardiff By The Sea, California, United States
Country:
United States
Status:
Active
Similar Organizations
Affini-T Therapeutics
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Employees Featured
Founder
More informations about "Stelios Therapeutics"
Stelios Therapeutics 2025 Company Profile: Valuation, Investors ...
Stelios Therapeutics was acquired by Lexeo Therapeutics. Data Transparency. Meet our data hygiene team. Discover how our experts ensure you’re getting the most accurate financial data …See details»
Lexeo Acquires Stelios to Expand Pipeline into Rare Cardiac Gene ...
Jul 21, 2021 “While we are in the early stages of applying the potential of AAV gene therapy to rare cardiac diseases, the possible therapeutic benefits across a broad number of previously …See details»
Lexeo snaps up Stelios, bolstering pipeline with trio of …
Jul 21, 2021 The assets come through Lexeo’s acquisition of Stelios Therapeutics, which was founded on research out of the University of California, San Diego. The company declined to disclose financial details.See details»
Stelios Therapeutics - Products, Competitors, Financials, …
Stelios Therapeutics develops novel adeno-associated virus-mediated gene therapies for rare genetic cardiac conditions. On July 21st, 2021, Stelios Therapeutics was acquired by LEXEO …See details»
Stelios Therapeutics - VentureRadar
Stelios Therapeutics is an early-stage company developing novel adeno-associated virus (AAV)-based gene therapies for rare genetic cardiac conditions. The biotech, originally called …See details»
LEXEO Therapeutics acquires Stelios Therapeutics - 2021-07-21 ...
Jul 21, 2021 Stelios Therapeutics Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. Acquiring Organization: …See details»
Stelios Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Explore Stelios Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 news, Technology Platform:Gene therapy, Drug:LX-2021. ... The statistics for drugs in the …See details»
Stelios Therapeutics - Crunchbase
Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
Stelios Therapeutics, Inc. - Company Profile - Corporation Wiki
May 10, 2017 Stelios Therapeutics, Inc. Overview. Stelios Therapeutics, Inc. filed as a Statement & Designation By Foreign Corporation in the State of California on Wednesday, …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy …
Jul 21, 2021 LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available Strategic acquisition expands …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline
Jul 21, 2021 Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. The company is founded based on research …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with ...
Jul 21, 2021 Stelios’ Scientific Co-founder and Professor of Medicine in Cardiology at the University of California San Diego School of Medicine (UC San Diego), Dr. Eric Adler, will …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with ...
Jul 22, 2021 LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, announced that it has acquired …See details»
LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with ...
NEW YORK, NY, USA I July 21, 2021 ILEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today …See details»
Lexeo keeps foot on the gas pedal with $100M financing to follow …
Sep 9, 2021 Lexeo Therapeutics isn’t wasting any time. The gene therapy biotech, which emerged in January with an all-star team of industry veterans, has raised $100 million to …See details»
Stelios Therapeutics - Contacts, Employees, Board Members, …
Stelios Therapeutics is an early-stage company developing novel AAV-based gene therapies for rare genetic cardiac conditions. Search Crunchbase. Start Free Trial . Chrome Extension. …See details»
Lexeo snaps up Stelios, bolstering pipeline with trio of rare heart ...
Jul 28, 2021 As Lexeo Therapeutics ushers two gene therapies toward the clinic, the company is adding another three heart disease programs to its already busy pipeline. The assets come …See details»
LEXEO收购Stelios Therapeutics，扩大心脏疾病基因治疗管道
⌈ByDrug医药新闻摘要⌋ 2021-08-03 09:05，药物简讯：-LEXEO 获得三个研究性 AAV 介导的罕见心脏疾病基因治疗项目的独家权利，所有这些项目都没有现有的疾病修饰疗法 -战略收购扩大 …See details»
Ovid Therapeutics : April 2025 Corporate Presentation
2 days ago Ovid Therapeutics Inc. Appoints Stelios Papadopoulos to Its Board of Directors and Member of Audit and Compensation Committees Mar. 03: CI Ovid Therapeutics Inc - Receives …See details»
Lexeo snaps up Stelios, bolstering pipeline with trio of rare heart ...
Jul 28, 2021 As Lexeo Therapeutics ushers two gene therapies toward the clinic, the company is adding another three heart disease programs to its already busy pipeline. The assets come …See details»